Could Aduhelm Be Taken Off Market If CMS Proposal Stands? ‘Everything Is On The Table,’ Biogen Says

Company execs say there has been four-fold increase in doctors infusing the Alzheimer’s drug and despite lack of support from major institutions, individual physicians at Cleveland Clinic and elsewhere have voiced support for Aduhelm. Biogen is “cautiously optimistic” about lecanemab Phase III trial.

Aducanumab — Alzheimer's disease drug Aduhelm (aducanumab) faces new hurdle with CMS national coverage decision • Source: Alamy

Could the Centers for Medicare & Medicaid Services’ draft national coverage decision to restrict Medicare payment for amyloid-targeting Alzheimer’s therapies be the death knell for Biogen/Eisai’s Aduhelm (aducanumab)?

That query arose during a 13 January investor call following the announcement of CMS’s decision, which limits Medicare coverage for...